OCEAN, said Albert, provides important risk-benefit data that doctors can now use in discussions with their patients. For ...

Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced its successful participation in the ...

The results of a late-stage drug trial released Thursday are raising hopes that type 1 diabetes patients with chronic kidney ...

If you ask a random person on the street what they call weight loss drugs, odds are, they are going to say Ozempic. It is one ...

A new trial co-led by the Ottawa Heart Institute and the Research Institute of the McGill University Health Centre shows that ...

ESTERO, FL / ACCESS Newswire / November 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today ...

A new trial co-led by the Ottawa Heart Institute and the Research Institute of the McGill University Health Centre shows that ...

What do Rollerblades and Ozempic have in common? Host Alex Hogan explains in the latest episode of STATus Report.

OCEAN was an open-label trial conducted in Australia, Belgium, Canada, China, Germany, and Israel. Eligible participants had ...

We had planes and automobiles abound in October’s new business winners, though sadly no trains, with some sizeable accounts ...

The FDA approved darolutamide for mHSPC on June 3, [2025], so we now have this in our armamentarium, along with all the other ...

The world’s most widely used weedkiller is confronting legal battles as well as a cat-and-mouse game with nature. But it’s ...